-8.5%
RGTI vs MRNA
+485.7%
-494.2%
-77.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | +5.4% | -4.7% | +0.6% |
| 7D | +0.5% | -1.1% | +1.5% | +0.5% |
| 30D | -17.1% | +126.1% | -143.2% | -20.0% |
| 3M | -26.0% | +190.0% | -216.0% | -35.5% |
| 6M | -9.9% | +157.2% | -167.1% | -18.3% |
| YTD | -31.1% | +388.2% | -419.3% | -48.8% |
| 1Y | -8.5% | +467.0% | -475.5% | -29.4% |
| All | -8.5% | +485.7% | -494.2% | -29.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling